In addition, increasing preclinical data suggest that there exists cross talk between hormonal receptor and growth factor receptors.[10, 21]Such cross talk can lead to synergistic tumor progression, differential sensitivity to therapies, and various patterns of tumor recurrence.[11, 22]Dual inhibition of hormonal receptor and growth factor receptor pathway may block such synergistic effect. The gene discussed is NR4A1; the disease is neoplasm.